Ursula Creutzig Selected Research

Therapeutics

5/2021	Survival Following Relapse in Children with Acute Myeloid Leukemia: A Report from AML-BFM and COG.
1/2020	Early deaths from childhood cancer in Germany 1980-2016.
12/2017	Characteristics and outcome in patients with central nervous system involvement treated in European pediatric acute myeloid leukemia study groups.
1/2017	Therapy reduction in patients with Down syndrome and myeloid leukemia: the international ML-DS 2006 trial.
2/2013	Improved outcome in pediatric relapsed acute myeloid leukemia: results of a randomized trial on liposomal daunorubicin by the International BFM Study Group.
10/2011	Integrative analysis of type-I and type-II aberrations underscores the genetic heterogeneity of pediatric acute myeloid leukemia.
10/2010	High-frequency type I/II mutational shifts between diagnosis and relapse are associated with outcome in pediatric AML: implications for personalized medicine.
6/2007	Longitudinal evaluation of early and late anthracycline cardiotoxicity in children with AML.
2/2007	Prophylactic human granulocyte colony-stimulating factor after induction therapy in pediatric acute myeloid leukemia.
11/2004	Emergence of translocation t(9;11)-positive leukemia during treatment of childhood acute lymphoblastic leukemia.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Ursula Creutzig Research Topics

Disease

35	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 05/2021 - 05/2003
8	Neoplasms (Cancer) 01/2020 - 03/2002
5	Down Syndrome (Down's Syndrome) 10/2018 - 06/2007
5	Infections 10/2016 - 11/2004
4	Acute Promyelocytic Leukemia 12/2017 - 05/2003
4	Leukemia 04/2009 - 04/2003
3	Myeloid Leukemia (Leukemia, Myelocytic) 10/2018 - 01/2016
3	Cardiotoxicity 07/2013 - 06/2007
3	Neutropenia 04/2009 - 09/2006
2	Residual Neoplasm 10/2018 - 01/2005
2	Liver Diseases (Liver Disease) 10/2018 - 03/2008
2	Cardiomyopathies (Cardiomyopathy) 07/2013 - 06/2007
2	Febrile Neutropenia 04/2009 - 02/2007
2	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 01/2006 - 11/2005
1	Hydrops Fetalis (Fetal Edema) 10/2018
1	Ascites 10/2018
1	Gastroenteritis 10/2016
1	Pneumonia (Pneumonitis) 10/2016
1	Bacteremia 10/2016
1	Fever of Unknown Origin 10/2016
1	Breast Neoplasms (Breast Cancer) 02/2016
1	Disease Progression 01/2016
1	Chromosome Aberrations (Chromosome Abnormalities) 06/2010
1	Lymphoma (Lymphomas) 04/2009
1	Pain (Aches) 06/2008
1	Thrombocytopenia (Thrombopenia) 03/2008
1	Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (T-ALL) 01/2006
1	Hyperbilirubinemia 05/2003
1	Hypotension (Low Blood Pressure) 05/2003

Drug/Important Bio-Agent (IBA)

5	Granulocyte Colony-Stimulating Factor (G-CSF)IBA 05/2010 - 12/2004
4	Cytarabine (Cytosar-U)FDA LinkGeneric 10/2018 - 12/2004
3	Proteins (Proteins, Gene)FDA Link 02/2016 - 06/2004
3	AnthracyclinesIBA 07/2013 - 06/2007
3	Daunorubicin (Cerubidine)FDA LinkGeneric 07/2013 - 06/2007
3	Core Binding Factors (Core-Binding Factor)IBA 11/2011 - 03/2011
2	Gemtuzumab (Mylotarg)FDA Link 01/2019 - 05/2003
2	Anti-Bacterial Agents (Antibiotics)IBA 10/2016 - 04/2009
2	Member 1 Subfamily B ATP Binding Cassette TransporterIBA 02/2016 - 06/2006
2	fludarabineIBA 01/2006 - 12/2004
1	RetinoidsIBA 08/2017
1	AcidsIBA 08/2017
1	Arsenic Trioxide (Trisenox)FDA Link 08/2017
1	ATP-Binding Cassette Transporters (ABC Transporters)IBA 02/2016
1	multidrug resistance-associated protein 3IBA 02/2016
1	Vorinostat FDA Link 01/2016
1	GlucocorticoidsIBA 01/2016
1	Histone Deacetylase InhibitorsIBA 01/2016
1	Histone Deacetylases (Histone Deacetylase)IBA 01/2016
1	Idarubicin (4 Demethoxydaunorubicin)FDA LinkGeneric 07/2013
1	Nuclear Pore Complex Proteins (Nucleoporins)IBA 09/2011
1	nuclear pore complex protein 98IBA 09/2011
1	CCAAT-Enhancer-Binding ProteinsIBA 03/2011
1	Tyrosine Kinase InhibitorsIBA 10/2010
1	SU 11657IBA 10/2010
1	Protein Isoforms (Isoforms)IBA 05/2010
1	Granulocyte Colony-Stimulating Factor Receptors (G-CSF Receptor)IBA 05/2010
1	Colony-Stimulating Factors (Colony Stimulating Factor)IBA 04/2009
1	Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)IBA 04/2009
1	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 04/2009
1	Cytochromes c (Cytochrome c)IBA 03/2008
1	Caspase 3 (Caspase-3)IBA 03/2008
1	Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA 02/2008
1	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 02/2008
1	Vascular Endothelial Growth Factor CIBA 02/2008
1	Antineoplastic Agents (Antineoplastics)IBA 06/2007
1	Cladribine FDA LinkGeneric 01/2006
1	tipifarnib (R115777)IBA 11/2005
1	TransferasesIBA 11/2005
1	AntigensIBA 01/2005
1	Cyclooxygenase 2 (Cyclooxygenase-2)IBA 01/2005
1	SurvivinIBA 06/2004
1	X-Linked Inhibitor of Apoptosis ProteinIBA 06/2004
1	Transaminases (Aminotransferases)IBA 05/2003
1	Tretinoin (Retinoic Acid)FDA LinkGeneric 05/2003

Therapy/Procedure

12	Therapeutics 05/2021 - 04/2003
12	Drug Therapy (Chemotherapy) 01/2019 - 03/2002
6	ICE protocol 4 08/2015 - 11/2004
4	Stem Cell Transplantation 01/2019 - 06/2008
3	Hematopoietic Stem Cell Transplantation 01/2020 - 12/2017
1	Salvage Therapy 01/2019
1	Aftercare (After-Treatment) 04/2003